THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 252.7 BDT | -0.32% |
|
-1.52% | -11.83% |
Valuation
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,844 | 9,270 | 8,954 | 7,895 | - | - |
| Enterprise Value (EV) 1 | 6,844 | 9,270 | 8,954 | 7,895 | 7,895 | 7,895 |
| P/E ratio | 17.8 x | 15.3 x | 14.8 x | 11.1 x | 9.72 x | 7.57 x |
| Yield | - | - | - | 2.81% | 3.21% | 4.08% |
| Capitalization / Revenue | 1.11 x | - | 0.98 x | 0.7 x | 0.62 x | 0.53 x |
| EV / Revenue | 1.11 x | - | 0.98 x | 0.7 x | 0.62 x | 0.53 x |
| EV / EBITDA | - | - | 8.23 x | 6.09 x | 5 x | 4.18 x |
| EV / FCF | - | - | 46.7 x | -28.4 x | 16.7 x | 12.1 x |
| FCF Yield | - | - | 2.14% | -3.52% | 6% | 8.28% |
| Price to Book | - | - | 2.96 x | 2.21 x | 1.89 x | 1.59 x |
| Nbr of stocks (in thousands) | 30,540 | 31,244 | 31,244 | 31,244 | - | - |
| Reference price 2 | 224.1 | 296.7 | 286.6 | 252.7 | 252.7 | 252.7 |
| Announcement Date | 20-10-21 | 22-10-04 | 23-09-30 | - | - | - |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 6,192 | - | 9,125 | 11,224 | 12,739 | 15,033 |
| EBITDA 1 | - | - | 1,088 | 1,296 | 1,580 | 1,887 |
| EBIT 1 | - | - | 860.4 | 1,059 | 1,213 | 1,500 |
| Operating Margin | - | - | 9.43% | 9.44% | 9.52% | 9.98% |
| Earnings before Tax (EBT) 1 | - | - | 804.7 | 946 | 1,080 | 1,385 |
| Net income 1 | - | 605.9 | 605.4 | 712 | 813 | 1,042 |
| Net margin | - | - | 6.63% | 6.34% | 6.38% | 6.93% |
| EPS 2 | 12.56 | 19.39 | 19.38 | 22.80 | 26.00 | 33.40 |
| Free Cash Flow 1 | - | - | 191.6 | -278 | 474 | 654 |
| FCF margin | - | - | 2.1% | -2.48% | 3.72% | 4.35% |
| FCF Conversion (EBITDA) | - | - | 17.62% | - | 30% | 34.66% |
| FCF Conversion (Net income) | - | - | 31.65% | - | 58.3% | 62.76% |
| Dividend per Share 2 | - | - | - | 7.100 | 8.100 | 10.30 |
| Announcement Date | 20-10-21 | 22-10-04 | 23-09-30 | - | - | - |
1BDT in Million2BDT
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2024 Q2 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS 1 | 6.700 |
| Dividend per Share | - |
| Announcement Date | 24-02-06 |
1BDT
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 192 | -278 | 474 | 654 |
| ROE (net income / shareholders' equity) | - | - | 21.5% | 21.5% | 21% | 22.8% |
| ROA (Net income/ Total Assets) | - | - | 13% | 12.6% | 12.5% | 14.8% |
| Assets 1 | - | - | 4,658 | 5,651 | 6,504 | 7,041 |
| Book Value Per Share 2 | - | - | 96.70 | 115.0 | 134.0 | 159.0 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 20-10-21 | 22-10-04 | 23-09-30 | - | - | - |
1BDT in Million2BDT
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
252.7
BDT
Average target price
390
BDT
Spread / Average Target
+54.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.83% | 67.59M | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- IBNSINA Stock
- Financials The IBN SINA Pharmaceutical Industry PLC
